<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01564992</url>
  </required_header>
  <id_info>
    <org_study_id>P 071240</org_study_id>
    <nct_id>NCT01564992</nct_id>
  </id_info>
  <brief_title>Drug Interaction With Genes in Parkinson's Disease</brief_title>
  <acronym>DIGPD</acronym>
  <official_title>Drug Interaction With Genes in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study aims at identifying gene modifiers of Parkinson Disease (PD) and of
      treatment response and adverse events of antiparkinsonian drugs. Six hundred PD patients will
      be followed annually for up to 5 years. A biological collection will be associated with a
      full clinical assessment of motor and non motor symptoms, medical and treatment history,
      environmental factors. The association between candidate gene polymorphisms and disease or
      treatment complications will be analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title : Drug interaction with genes in Parkinson Disease

      Objective:

      To identify genes associated to disease and treatment complication and response.

      Number of subjects: 500

      Study duration : 6 years

      Design:

      Prospective cohort with biological collection

      Primary objective:

      Identification of genes which polymorphism or haplotype is associated with a complication of
      Parkinson disease, directly or with the interaction of treatment.

      Secondary objectives:

        -  Prevalence and incidence of disease or treatment complications

        -  Clinical risk factor for disease or treatment complications

        -  Biomarkers of disease progression, disease or treatment complications
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All complications of the disease or treatment</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson disease</arm_group_label>
    <description>Identification of genes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Identification of genes</intervention_name>
    <description>Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.</description>
    <arm_group_label>Parkinson disease</arm_group_label>
    <other_name>polymorphism or haplotype</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women adults with a Parkinson Disease according to UKPDSBB criteria, diagnosed &lt; 6
        years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, age &gt; 18.

          -  Parkinson Disease according to UKPDSBB criteria

          -  PD diagnosis &lt; 6 years

          -  Informed consent

        Exclusion Criteria:

        - Atypical parkinsonism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Corvol, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asssitance Publique - Hopitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe Corvol, MD, PhD</last_name>
    <phone>+33 1 42 16 57 66</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Neuro - Bâtiment ICM - Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Corvol, MD, PhD</last_name>
      <phone>+33 1 42 16 57 66</phone>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Corvol, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

